Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis
Our findings indicated a lower incidence of all-cause mortality and MACE after long-term follow-up, along with a higher likelihood of achieving dialysis-free status at 90 days in SGLT-2i users. Importantly, they underscored the potential cardiovascular protection and safety of SGLT-2is use in T2DM patients at the onset of dialysis.
Authors
- Vin‐Cent Wu (ORCID: https://orcid.org/0000-0001-7935-0991)
- Shuo‐Meng Wang (ORCID: https://orcid.org/0000-0003-2090-1757)
- Jui‐Yi Chen (ORCID: https://orcid.org/0000-0003-1376-7780)
- Li‐Chun Lin
- Chung-An Wang (ORCID: https://orcid.org/0009-0005-2537-9146)
Institutions
- Chung Yuan Christian University (TW)
- Tao Yuan General Hospital (TW)
- National Taiwan University Hospital (TW)
- Chi Mei Medical Center (TW)
- Taipei Medical University (TW)
- Chia Nan University of Pharmacy and Science (TW)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1186/s12933-024-02424-7
- Citations
- 12
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 4.29